학술논문

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
Document Type
article
Author
Ovarian Tumor Tissue Analysis (OTTA) ConsortiumGoode, Ellen LBlock, Matthew SKalli, Kimberly RVierkant, Robert AChen, WenqianFogarty, Zachary CGentry-Maharaj, AleksandraTołoczko, AleksandraHein, AlexanderBouligny, Aliecia LJensen, AllanOsorio, AnaHartkopf, AndreasRyan, AndyChudecka-Głaz, AnitaMagliocco, Anthony MHartmann, ArndtJung, Audrey YGao, BoHernandez, Brenda YFridley, Brooke LMcCauley, Bryan MKennedy, Catherine JWang, ChenKarpinskyj, Chloede Sousa, Christiani BTiezzi, Daniel GWachter, David LHerpel, EstherTaran, Florin AndreiModugno, FrancesmaryNelson, GreggLubiński, JanMenkiszak, JanuszAlsop, JenniferLester, JennyGarcía-Donas, JesúsNation, JillHung, JillianPalacios, JoséRothstein, Joseph HKelley, Joseph Lde Andrade, Jurandyr MRobles-Díaz, LuisIntermaggio, Maria PWidschwendter, MartinBeckmann, Matthias WRuebner, MatthiasJimenez-Linan, MercedesSingh, NaveenaOszurek, OlegHarnett, Paul RRambau, Peter FSinn, PeterWagner, PhilippGhatage, PrafullSharma, RaghwaEdwards, Robert PNess, Roberta BOrsulic, SandraBrucker, Sara YJohnatty, Sharon ELongacre, Teri AUrsula, EilberMcGuire, ValerieSieh, WeivaNatanzon, YaninaLi, ZhengWhittemore, Alice SAnna, deFazioStaebler, AnnetteKarlan, Beth YGilks, BlakeBowtell, David DHøgdall, EstridCandido dos Reis, Francisco JSteed, HelenCampbell, Ian GGronwald, JacekBenítez, JavierKoziak, Jennifer MChang-Claude, JennyMoysich, Kirsten BKelemen, Linda ECook, Linda SGoodman, Marc TGarcía, María JoséFasching, Peter AKommoss, StefanDeen, SuhaKjaer, Susanne KMenon, UshaBrenton, James DPharoah, Paul DPChenevix-Trench, GeorgiaHuntsman, David GWinham, Stacey JKöbel, MartinRamus, Susan J
Source
JAMA oncology. 3(12)
Subject
Ovarian Tumor Tissue Analysis (OTTA) Consortium
Lymphocytes
Tumor-Infiltrating
Humans
Cystadenocarcinoma
Serous
Ovarian Neoplasms
BRCA2 Protein
Treatment Outcome
Survival Analysis
Cohort Studies
Prospective Studies
Mutation
Middle Aged
Female
Neoplasm Grading
CD8 Antigens
Carcinoma
Ovarian Epithelial
Lymphocytes
Tumor-Infiltrating
Cystadenocarcinoma
Serous
Carcinoma
Ovarian Epithelial
Cancer
Prevention
Ovarian Cancer
Rare Diseases
Vaccine Related
Clinical Research
Oncology and Carcinogenesis
Public Health and Health Services
Language
Abstract
ImportanceCytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors.ObjectiveTo define the prognostic role of CD8+ TILs in epithelial ovarian cancer.Design, setting, and participantsThis was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years.ExposuresFollowing immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines.Main outcomes and measuresOverall survival time.ResultsThe final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form.Conclusions and relevanceThis study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.